10,625 reports of this reaction
8.6% of all TENOFOVIR DISOPROXIL FUMARATE reports
#1 most reported adverse reaction
BONE DENSITY DECREASED is the #1 most commonly reported adverse reaction for TENOFOVIR DISOPROXIL FUMARATE, manufactured by Gilead Sciences, Inc.. There are 10,625 FDA adverse event reports linking TENOFOVIR DISOPROXIL FUMARATE to BONE DENSITY DECREASED. This represents approximately 8.6% of all 123,510 adverse event reports for this drug.
TENOFOVIR DISOPROXIL FUMARATE has an overall safety score of 92 out of 100. Patients taking TENOFOVIR DISOPROXIL FUMARATE who experience bone density decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BONE DENSITY DECREASED is moderately reported among TENOFOVIR DISOPROXIL FUMARATE users, representing a notable but not dominant share of adverse events.
In addition to bone density decreased, the following adverse reactions have been reported for TENOFOVIR DISOPROXIL FUMARATE:
The following drugs have also been linked to bone density decreased in FDA adverse event reports:
BONE DENSITY DECREASED has been reported as an adverse event in 10,625 FDA reports for TENOFOVIR DISOPROXIL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BONE DENSITY DECREASED accounts for approximately 8.6% of all adverse event reports for TENOFOVIR DISOPROXIL FUMARATE, making it one of the most commonly reported side effect.
If you experience bone density decreased while taking TENOFOVIR DISOPROXIL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.